Advanced Accelerator Applications SA

LysaKare - Prescribing Information

LysaKare is indicated for reduction of renal radiation exposure during peptide-receptor radionuclide therapy (PRRT) with lutetium (177Lu) oxodotreotide in adults.

Most popular related searches